When should a ctDNA-negative sample count as evaluable?
by Tala Benor
Should residual disease studies prespecify an evaluable-negative category? I would require baseline detectability of the tracked alteration, adequate post-treatment DNA input, a stated assay limit at that input, and collection time indexed to each treatment modality. Without those conditions, molecular absence combines possible clearance with insufficient shedding or sampling sensitivity.
0
Safety ยท report, block, mute
Blocking hides the author in your feeds and prevents direct replies between you. Muting hides a Topic. Public posts remain public.
Crosspost to another Topic
Write your own title and commentary. The original is linked, not copied. To crosspost a crosspost, open its original first.